MedTrace Logo

Sentinel Node Detection With Technetium-99m Albumin Nanocolloid and ICG in Patients With Epithelial Ovarian Cancer

NCT05937620 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-02-09

No results posted yet for this study

Summary

Study to evaluate the diagnostic precision of ICG and 99mTc nanocolloid albumin in sentinel lymph node detection in early ovarian epithelial cancer.

Conditions

  • Ovarian Epithelial Cancer

Interventions

DIAGNOSTIC_TEST

99mTC nanocolloid albumin injection

All patients will receive an injection of both tracers in order to detect the sentinel lymph node

DIAGNOSTIC_TEST

ICG injection

All patients will receive an injection of both tracers in order to detect the sentinel lymph node

Sponsors & Collaborators

  • Fundacion Clinic per a la Recerca Biomédica

    lead OTHER

Principal Investigators

  • Berta Diaz-Feijoo, Physician · Hospital Clinic of Barcelona

  • Aureli Torné, Physician · Hospital Clinic of Barcelona

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05937620 on ClinicalTrials.gov